The Analgesics market comprises over-the-counter natural and synthetic non-opioid analgesics (only in approved low doses) like Paracetamol, Ibuprofen, Aspirin, Diclofenac and other pain-relieving preparations. Legislation on opioid analgesics differs from country to country. According to the respective state legislation, legal opioid analgesics are included. In Germany, Austria and Switzerland, for instance, opioid analgesics are only included if they are not limited by the narcotics law and do not require prescription. Analgesics are included in the form of pills, capsules, gels and ointments. Not included are prescription medicines (e.g. morphine), anesthetics and homeopathic remedies. Among the top-selling painkillers are Voltaren, Aspirin, Thomapyrin, Ibuprofen, Dolormin, Paracetamol and ASS. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.
The Analgesics market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.
Over-the-counter analgesics (e.g. Aspirin and Paracetamol)
Natural and synthetic agents
In the form of pills, capsules, gels and ointments
Although the COVID-19 pandemic resulted in a reduction of selective procedures and surgeries, which leads to a decreasing sale of after-surgical pain killers, COVID-19-related symptoms such as muscle or body aches are driving the demand during the pandemic. In 2022, the global Analgesics market reached US$30.93 billion and recovered from a slight decline in 2020 brought about by the COVID-19 pandemic.
Another significant trend is the prevalence of chronic diseases, which leads to a growing demand for analgesics used by people suffering from chronic and severe pain. The growth of the Analgesics market is restricted by legislation, as the restriction on opioid analgesics differs from country to country.
In the forecast period, the market exhibits steady growth at a CAGR of around 6%, mainly based on the globally growing share of the elderly population and the correspondingly increasing demand. The global Analgesics market is expected to reach US$42.65 billion in 2027.
The Analgesics market is built on resources from the Statista platform as well as on in-house market research, national statistical offices, international institutions, trade associations, companies, the trade press, and the experience of our analysts. We evaluate the status quo of the market, monitor trends, and create an independent forecast regarding market developments of the global Analgesics industry.